Clinical Trials
302 trialsNCT02112565 2025-07-04
RNR Inhibitor COH29 in Treating Patients With Solid Tumors That Are Refractory to Standard Therapy or For Which No Standard Therapy Exists
City of Hope Medical Center
Phase 1 Active not recruiting
NCT00483366 2024-09-23
Imatinib Mesylate, Gemcitabine, and Capecitabine in Treating Patients With Advanced Solid Tumors
University of Nebraska
Phase 1 Completed
NCT04842630 2024-02-09
A Phase 1 Dose Escalation and Expansion Study Of SHR-1916 In Subjects With Locally Advanced Or Metastatic Solid Tumors
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Terminated
NCT01206465 2023-12-26
Pralatrexate and Fluorouracil in Treating Patients With Recurrent Solid Tumors
University of Nebraska
Phase 1 Completed
NCT03859752 2023-09-22
TR1801-ADC in Patients With Tumors That Express c-Met
Open Innovation Partners, Inc.
Phase 1 Suspended
NCT00084734 2023-08-04
Docetaxel, Capecitabine, and Cisplatin in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Completed
NCT00357747 2023-08-04
AEG35156 and Docetaxel in Treating Patients With Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00372736 2023-08-04
AEG35156 and Docetaxel in Treating Patients With Locally Advanced, Metastatic, or Recurrent Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00504296 2023-08-04
SB939 in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT01642342 2022-08-24
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
University of Southern California
Phase 1 Terminated
NCT01573780 2022-08-15
Gemcitabine Hydrochloride and Smac Mimetic TL32711 in Treating Patients With Advanced Solid Tumors
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01527136 2022-07-22
Entolimod in Treating Patients With Locally Advanced or Metastatic Solid Tumors That Cannot Be Removed By Surgery
Roswell Park Cancer Institute
Phase 1 Completed
NCT01540253 2022-07-22
PI3K Inhibitor BKM120 and Docetaxel in Treating Patients With Advanced Solid Tumor That is Locally Advanced, Cannot Be Removed By Surgery, or Metastatic
Roswell Park Cancer Institute
Phase 1 Completed
NCT00091299 2020-08-05
Warfarin and Vatalanib in Treating Patients With Advanced Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT01470365 2020-05-08
3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Recurrent Tumors
Fox Chase Cancer Center
Phase 1 Completed
NCT00003891 2020-04-09
Lurtotecan Liposome in Treating Patients With Advanced Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00003890 2020-04-06
MG98 in Treating Patients With Advanced Solid Tumors
Canadian Cancer Trials Group
Phase 1 Completed
NCT00645060 2020-02-27
Yttrium Y 90 DOTA Anti-CEA Monoclonal Antibody M5A in Treating Patients With Advanced Solid Tumors
City of Hope Medical Center
Phase 1 Completed
NCT00004872 2019-12-13
Endostatin in Treating Patients With Advanced Refractory Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT00005794 2019-12-13
Perifosine in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT00023855 2019-12-13
PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT02146222 2019-11-18
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
University of Wisconsin, Madison
Phase 1 Completed
NCT01791088 2019-04-22
Sirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery
University of Chicago
Phase 1 Completed
NCT00909831 2019-04-16
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00390000 2019-04-08
Vatalanib and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Completed
NCT00002902 2019-03-13
Irinotecan Plus ICI D1694 in Treating Patients With Advanced Solid Tumors
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT01713972 2019-03-01
Dabrafenib and Pazopanib Hydrochloride in Treating Patients With Advanced Malignant Tumors
Ohio State University Comprehensive Cancer Center
Phase 1 Completed
NCT02070406 2019-02-28
Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT00892385 2019-02-22
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
Case Comprehensive Cancer Center
Phase 1 Completed
NCT00096317 2018-10-31
Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT00004863 2018-09-10
Paclitaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT00004864 2018-09-10
Docetaxel and GEM 231 in Treating Patients With Recurrent or Refractory Solid Tumors
Montefiore Medical Center
Phase 1 Completed
NCT00003713 2018-08-29
Chemotherapy in Treating Patients With Advanced or Metastatic Solid Tumors
Sanofi
Phase 1 Completed
NCT00003822 2018-08-29
SR-45023A in Treating Patients With Advanced Solid Tumors
Sanofi
Phase 1 Completed
NCT00004049 2018-08-29
SR-45023A in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Sanofi
Phase 1 Completed
NCT01705106 2018-05-30
Capecitabine and Celecoxib in Patients With Solid Cancers That Have Been Previously Treated With Standard Therapies
University of Chicago
Phase 1 Terminated
NCT00290680 2018-04-10
Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors
Medical University of South Carolina
Phase 1 Completed
NCT00014261 2018-03-30
Temozolomide Plus PEG-Interferon Alfa-2B in Treating Patients With Advanced Solid Tumors
Dartmouth-Hitchcock Medical Center
Phase 1 Completed
NCT00098514 2017-12-18
Talotrexin in Treating Patients With Advanced or Recurrent Solid Tumors
Dana-Farber Cancer Institute
Phase 1 Completed
NCT00541359 2017-08-09
Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors
City of Hope Medical Center
Phase 1 Completed
NCT00471562 2017-08-01
Angiotensin-(1-7) in Treating Patients With Metastatic or Unresectable Solid Tumors
Wake Forest University Health Sciences
Phase 1 Completed
NCT00610948 2017-05-04
Everolimus, Fluorouracil, Leucovorin, Panitumumab, and Oxaliplatin in Treating Patients With Tumors That Did Not Respond to Treatment
UNC Lineberger Comprehensive Cancer Center
Phase 1 Completed
NCT01957995 2017-04-11
Nanosomal Docetaxel Lipid Suspension in Treating Patients With Advanced Solid Tumors
University of Southern California
Phase 1 Completed
NCT00731276 2017-03-31
Irinotecan in Treating Asian Patients With Solid Tumors
National Cancer Centre, Singapore
Phase 1 Completed
NCT00878904 2017-03-24
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors
University of California, San Francisco
Phase 1 Completed
NCT00662636 2017-03-23
Dasatinib and Lapatinib Ditolsylate in Treating Patients With Advanced Solid Tumors That Cannot Be Removed By Surgery
Mayo Clinic
Phase 1 Completed
NCT00004927 2017-01-30
BMS-247550 in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy
R-Pharm
Phase 1 Completed
NCT00003899 2016-10-04
Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Recurrent or Refractory Solid Tumors
Fred Hutchinson Cancer Center
Phase 1 Completed
NCT00019565 2016-09-26
PET and/or MRI Scans in Assessing Tumor Response in Patients Receiving Antiangiogenesis Therapy
National Institutes of Health Clinical Center (CC)
Phase 1 Completed
NCT00416637 2016-07-07
Bevacizumab in Treating Patients With Advanced Solid Tumors
Duke University
Phase 1 Completed